M-A | Incidence of cutaneous adverse events with Phosphoinositide 3-Kinase inhibitors as adjuvant therapy in patients with cancer.
14 Oct, 2022 | 14:01h | UTCIncidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis – JAMA Oncology (free for a limited period)